Maze Therapeutics

MAZE

Market cap $1.37B

Maze Therapeutics, Inc. (MAZE) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 Transcript

SOUTH SAN FRANCISCO, Calif., May 27, 2026 (GLOBE NEWSWIRE) -- Maze Therapeutics, Inc. (Nasdaq: MAZE), a clinical-stage biopharmaceutical company developing small molecule precision medicines for patients with kidney and metabolic diseases, today announced that Jason Coloma, Ph.D., chief executive officer of Maze Therapeutics, will participate in two upcoming investor conferences:

Maze Therapeutics, Inc. (MAZE) came out with a quarterly loss of $0.45 per share versus the Zacks Consensus Estimate of a loss of $0.43. This compares to a loss of $1.15 per share a year ago.

Positive topline data from Phase 2 HORIZON trial of MZE829 in patients with broad AMKD provide proof-of-concept and support advancement into pivotal trial; additional HORIZON data expected in late 2026 or early 2027 Phase 2 proof-of-concept clinical trials evaluating MZE782 in PKU and CKD on track to initiate in 2026 Strong balance sheet with $528 million in cash, cash equivalents and marketable securities; inclusive of net proceeds from the $150 million registered offering and $20 million MZE001 milestone payment in April 2026; cash runway expected to extend into 2029 SOUTH SAN FRANCISCO, Calif., May 12, 2026 (GLOBE NEWSWIRE) -- Maze Therapeutics, Inc. (Nasdaq: MAZE), a clinical-stage biopharmaceutical company developing small molecule precision medicines for patients with kidney and metabolic diseases, today reported financial results for the first quarter ended March 31, 2026, highlighting recent progress and business updates.

SOUTH SAN FRANCISCO, Calif., April 22, 2026 (GLOBE NEWSWIRE) -- Maze Therapeutics, Inc. (Nasdaq: MAZE) today announced the pricing of its underwritten registered offering of 5,540,000 shares of its common stock at a price of $23.50 per share. In addition, and in lieu of common stock, Maze is offering to certain investors pre-funded warrants to purchase up to an aggregate of 850,000 shares of common stock at a purchase price of $23.499 per pre-funded warrant, which represents the per share price for the common stock less the $0.001 per share exercise price for each such pre-funded warrant. The gross proceeds to Maze from the offering, before deducting underwriting discounts and commissions and other offering expenses payable by Maze, are expected to be $150 million. The offering is expected to close on or about April 23, 2026, subject to the satisfaction of customary closing conditions. All of the securities are being offered by Maze.

Chief Medical Officer Harold Bernstein sold 15,000 company shares for a transaction value of ~$442,000 at around $29.46 per share on April 1, 2026. This disposition represented 100% of Harold Bernstein's direct Common Stock holdings, reducing his direct ownership of Common Stock to zero.

I am initiating coverage on Maze Therapeutics (MAZE) with a "Buy" rating following positive phase 2 HORIZON data for MZE829 in APOL1-mediated kidney disease. MZE829 achieved a 35.6% mean reduction in proteinuria, exceeding the ≥30% uACR threshold required for clinical relevance and potential regulatory advancement. Despite a 37% stock drop post-data, I view the market reaction as overblown given the program's success and planned pivotal trial initiation.

The heavy selling pressure might have exhausted for Maze Therapeutics, Inc. (MAZE) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall Street analysts in revising earnings estimates higher indicates that the stock is ripe for a trend reversal.

SAN DIEGO, March 26, 2026 (GLOBE NEWSWIRE) -- Johnson Fistel, PLLP is investigating potential claims on behalf of investors of Maze Therapeutics, Inc. (NASDAQ: MAZE). The investigation focuses on Maze's executive officers and whether investor losses may be recovered under federal securities laws.

An executive at Maze Therapeutics reported selling 15,000 shares on March 20, 2026, yielding a transaction value of $736,000 at around $49.10 per share. The activity was executed directly, involved derivative mechanics (option exercise), and did not affect any indirect holdings.